Improvement of TNM staging for medullary thyroid cancer
Menée à partir des données de registres américains portant sur 3 315 patients atteints d'un cancer médullaire de la thyroïde, cette étude analyse la corrélation entre le système de stadification TNM de l'"American Joint Committee on Cancer" et la survie des patients
Medullary thyroid cancer (MTC) accounts for less than 5% of all thyroid cancers; it differs from the more common papillary thyroid cancer and follicular thyroid cancer, which collectively are called differentiated thyroid cancer. Medullary TC derives from C cells instead of follicular cells and is considered a neuroendocrine tumor. Although most MTC grows slowly, the prognosis of patients with MTC is worse than that of patients with papillary thyroid cancer or follicular thyroid cancer. A high proportion of MTC is associated with germline RET (rearranged during transfection) oncogene mutation as part of the multiple endocrine neoplasia type 2 syndrome.1
JAMA Surgery , commentaire, 2016